‘In order to curtail the oncology treatment cost in the US, USFDA approved generic cancer drugs’, says RNCOS.
Noida, UP -- (SBWIRE) -- 01/16/2015 -- GLOBOCAN estimates predict a substantive increase to 19.3 Million new cancer cases per year by 2025, due to growth and ageing of the global population. According to the National Cancer Institute's estimates, nearly 232,340 women would be diagnosed with and 39,620 women would die of breast cancer in 2013. The 5 year survival rate for a stage IV breast cancer patient is only 22%. Breast cancer is now the most common cancer both in developed and developing regions. The occurrence of breast cancer is ever-increasing in the developing world owing to adoption of western lifestyles, increase in life expectancy, and increase in urbanization.
Breast cancer is the focus of manufacturers dealing with branded and generic drugs. In the past 2-3 years, key blockbuster drugs, such as Femara (used only in the breast cancer treatment), Gemzar and Taxotere had become off-patent. FDA has already approved a dozen new generic versions of Femara manufactured by big names, such as Teva Pharmaceuticals, Dr. Reddy's Labs, Sun Pharmaceutical Industries, Impax Labs, Endo Pharmaceuticals, Roxane Labs, Accord Healthcare, etc. The cancer generics market is anticipated to grow at a CAGR of around 12% during 2013-2018.
Holistically, RNCOS' latest research report "Global Cancer Generics Market Outlook 2018", elicits the global oncology market and global caner generics market, cancer incidences are discussed providing an insight about the geographical share and country wise incidence rate. Furthermore, the generic cancer drugs are scrutinized according to their dosage form. In addition to that, the cancer generics industry with respect to the major indications is also discussed in depth, emphasis on current and future incidence, regional analysis and the patent expiration status of key cancer drugs. Analysis of key industry trends and drivers crucial to the market is also added. Moreover, the dossier also contains the analysis of the top notch global cancer generics manufacturers. On the holistic basis, the report is primarily inclined towards the in-depth study of global cancer generics market, asserting the fact that Cancer Generics is going to be the focus area for several industry players, thereby labeling Cancer Generics as a field with substantial growth potential over the next few years.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM704.htm
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.